Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease

Author(s): Amy L. Lightner*, Edward V. Loftus, Nicholas P. McKenna, Laura E. Raffals.

Journal Name: Current Drug Targets

Volume 20 , Issue 13 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications.

Objective: To determine the risk of vedolizumab on postoperative complications.

Methods: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn’s disease or ulcerative colitis individually, and those which included pediatric patients alone.

Results: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn’s disease literature.

Conclusion: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn’s disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.

Keywords: Vedolizumab, inflammatory bowel disease, surgical intervention, postoperative infectious complications, intraabdominal sepsis, Crohn’s disease, ulcerative colitis.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 13
Year: 2019
Page: [1317 - 1322]
Pages: 6
DOI: 10.2174/1389450120666190325130142
Price: $58

Article Metrics

PDF: 14